$TLIS
Talis Biomedical Corp

2023 Q1 Form 10-K Financial Statement

#000095017023009197 Filed on March 22, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $1.218M $257.0K $4.812M
YoY Change -61.78% -70.05% -41.27%
Cost Of Revenue $20.00K $2.332M $8.391M
YoY Change -99.43%
Gross Profit $1.198M -$2.075M -$3.579M
YoY Change -458.68% -143.68%
Gross Profit Margin 98.36% -807.39% -74.38%
Selling, General & Admin $6.399M $10.80M $40.73M
YoY Change -46.36% -12.35% -3.98%
% of Gross Profit 534.14%
Research & Development $13.80M $15.24M $70.83M
YoY Change -33.36% -10.67% -55.05%
% of Gross Profit 1151.59%
Depreciation & Amortization $174.0K $3.562M $6.600M
YoY Change -52.07% 280.15% 312.5%
% of Gross Profit 14.52%
Operating Expenses $20.20M $26.04M $111.6M
YoY Change -38.11% -11.37% -44.22%
Operating Profit -$19.00M -$28.11M -$115.1M
YoY Change -42.38% -39.97%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.166M $1.183M $2.127M
YoY Change -1488.1% -982.84% -1066.82%
Pretax Income -$17.83M -$26.93M -$113.0M
YoY Change -46.05% -6.02% -41.15%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$17.83M -$26.93M -$113.0M
YoY Change -46.05% -6.02% -41.15%
Net Earnings / Revenue -1463.96% -10478.21% -2348.55%
Basic Earnings Per Share -$0.66 -$4.24
Diluted Earnings Per Share -$0.66 -$0.98 -$4.24
COMMON SHARES
Basic Shares Outstanding 56.73M 56.65M 26.63M
Diluted Shares Outstanding 26.82M 26.63M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $113.0M $130.2M $130.2M
YoY Change -39.78% -44.01% -44.01%
Cash & Equivalents $113.0M $130.2M
Short-Term Investments
Other Short-Term Assets $2.502M $2.783M $2.783M
YoY Change -64.95% -17.83% -17.83%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $115.6M $133.3M $133.3M
YoY Change -42.44% -43.55% -43.55%
LONG-TERM ASSETS
Property, Plant & Equipment $3.634M $3.312M $34.23M
YoY Change -66.24% -68.54% 46.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.542M $1.776M $1.776M
YoY Change -75.55% -71.71% -71.71%
Total Long-Term Assets $17.47M $36.01M $36.01M
YoY Change -41.32% 21.19% 21.19%
TOTAL ASSETS
Total Short-Term Assets $115.6M $133.3M $133.3M
Total Long-Term Assets $17.47M $36.01M $36.01M
Total Assets $133.1M $169.3M $169.3M
YoY Change -42.3% -36.32% -36.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.871M $3.768M $3.768M
YoY Change -26.45% -26.43% -26.43%
Accrued Expenses $1.614M $989.0K $8.904M
YoY Change -53.83% -84.51% -31.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.18M $12.67M $12.67M
YoY Change -26.81% -33.68% -33.68%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $11.75M $29.88M $29.88M
YoY Change -6.2% 134.44% 134.44%
Total Long-Term Liabilities $11.75M $29.88M $29.88M
YoY Change -6.2% 134.44% 134.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.18M $12.67M $12.67M
Total Long-Term Liabilities $11.75M $29.88M $29.88M
Total Liabilities $22.93M $42.55M $42.55M
YoY Change -17.53% 33.59% 33.59%
SHAREHOLDERS EQUITY
Retained Earnings -$495.8M -$478.0M
YoY Change 24.57% 30.97%
Common Stock $605.9M $604.7M
YoY Change 0.85% 0.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $110.1M $126.7M $126.7M
YoY Change
Total Liabilities & Shareholders Equity $133.1M $169.3M $169.3M
YoY Change -42.3% -36.32% -36.32%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$17.83M -$26.93M -$113.0M
YoY Change -46.05% -6.02% -41.15%
Depreciation, Depletion And Amortization $174.0K $3.562M $6.600M
YoY Change -52.07% 280.15% 312.5%
Cash From Operating Activities -$16.47M -$13.54M -$100.1M
YoY Change -62.37% -66.76% -41.57%
INVESTING ACTIVITIES
Capital Expenditures $24.00K $49.00K $1.615M
YoY Change -95.27% -104.96% -43.65%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$24.00K -$49.00K -$1.615M
YoY Change -95.27% -95.04% -43.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 33.00K 0.000 406.0K
YoY Change -89.49% -100.0% -99.83%
NET CHANGE
Cash From Operating Activities -16.47M -13.54M -100.1M
Cash From Investing Activities -24.00K -49.00K -1.615M
Cash From Financing Activities 33.00K 0.000 406.0K
Net Change In Cash -16.46M -13.59M -101.3M
YoY Change -62.56% -66.9% -268.41%
FREE CASH FLOW
Cash From Operating Activities -$16.47M -$13.54M -$100.1M
Capital Expenditures $24.00K $49.00K $1.615M
Free Cash Flow -$16.49M -$13.59M -$101.8M
YoY Change -62.75% -65.81% -41.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001584751
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-40047
CY2022 dei Entity Registrant Name
EntityRegistrantName
Talis Biomedical Corporation
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-3122255
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
3400 Bridge Parkway
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94065
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6383000
CY2022 dei City Area Code
CityAreaCode
650
CY2022 dei Local Phone Number
LocalPhoneNumber
433-3000
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2022 dei Trading Symbol
TradingSymbol
TLIS
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
7342048000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
56730589
CY2022 dei Auditor Firm
AuditorFirmId
42
CY2022 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2022 dei Auditor Location
AuditorLocation
Chicago, Illinois
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
130191000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
232545000
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
308000
CY2021Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
183000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2783000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3387000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
133282000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
236115000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3312000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10528000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
30920000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12907000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1776000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6278000
CY2022Q4 us-gaap Assets
Assets
169290000
CY2021Q4 us-gaap Assets
Assets
265828000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3768000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5122000
CY2022Q4 tlis Accrued Compensation Current
AccruedCompensationCurrent
4212000
CY2021Q4 tlis Accrued Compensation Current
AccruedCompensationCurrent
6369000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
989000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3703000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1232000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12672000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19106000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-108571000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1444000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
439000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
232548000
CY2021 tlis Reclassifications Of Temporary Equity To Permanent Equity Common Stock And Series One
ReclassificationsOfTemporaryEquityToPermanentEquityCommonStockAndSeriesOne
290946000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29879000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12745000
CY2022Q4 us-gaap Liabilities
Liabilities
42551000
CY2021Q4 us-gaap Liabilities
Liabilities
31851000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26795800
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26795800
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26408031
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26408031
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
604687000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
598913000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-477954000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-364942000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
126739000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
233977000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
169290000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
265828000
CY2022 us-gaap Revenues
Revenues
4812000
CY2021 us-gaap Revenues
Revenues
8193000
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8391000
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70831000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
157591000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
40729000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
42418000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
119951000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
200009000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-115139000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-191816000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2127000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-220000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-113012000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-192036000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.24
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.24
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.48
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.48
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26633241
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26633241
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22655339
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22655339
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9207000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-192036000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
233977000
CY2022 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
98000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
308000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5368000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-113012000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
126739000
CY2022 us-gaap Profit Loss
ProfitLoss
-113012000
CY2021 us-gaap Profit Loss
ProfitLoss
-192036000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
5368000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
9207000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
8830000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1578000
CY2022 tlis Noncash Lease Expense
NoncashLeaseExpense
2771000
CY2021 tlis Noncash Lease Expense
NoncashLeaseExpense
1043000
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
3593000
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 tlis Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
125000
CY2021 tlis Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-288000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-604000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
281000
CY2022 tlis Increase Decrease In Prepaid Research And Development
IncreaseDecreaseInPrepaidResearchAndDevelopment
0
CY2021 tlis Increase Decrease In Prepaid Research And Development
IncreaseDecreaseInPrepaidResearchAndDevelopment
-12014000
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
-741000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
5615000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1194000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
216000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-7712000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2202000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-100136000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-171384000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1615000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2866000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1615000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2866000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
98000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1444000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
308000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
439000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
232546000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
406000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
234429000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-101345000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
60179000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
233312000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
173133000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
131967000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
233312000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
19245000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
13499000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
130191000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
232545000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1776000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
767000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
131967000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
233312000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-113000000.0
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
130200000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
1800000
CY2022Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
0
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions, including knowledge about current events and expectations about actions the Company may take in the future, that the Company believes are reasonable under the circumstances. Actual results could vary from the amounts derived from management’s estimates and assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, the Company shortened the useful life of certain lab equipment as a result of manufacturing changes brought about by the decision to no longer pursue the commercialization of the stand-alone Talis One COVID-19 test in the United States. This change in estimate resulted in $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of accelerated depreciation expense during the twelve months ended December 31, 2022.</span></p>
CY2022 us-gaap Depreciation
Depreciation
6600000
CY2022 us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product revenue, net</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company currently only generates revenues from its sales of third-party Antigen Tests. The Company obtains control of the product and assumes inventory risk before it is transferred to the customer and therefore reports revenue on the gross amount billed to the customer. The Company has recognized sales from two primary customer types: (i) direct customers including hospitals, urgent care centers, physician, public health and retail clinics, and (ii) sub-distributors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes revenue under Accounting Standards Codification Topic 606 (ASC 606), </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">when a customer obtains control of promised goods or services, with a transaction price that reflects the consideration which the entity expects to receive in exchange for those goods or services. Transaction price does not include amounts subject to uncertainties unless it is probable that there will be no significant reversal of revenue when the uncertainty is resolved. If necessary, revenue is recorded net of variable consideration based on the amounts the Company expects to be earned or to be claimed on the related sales. The Company estimates the amount of its product sales that may result in returns or in price adjustments and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The returned assets cannot be re-sold and have no value to the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company identifies the contract with a customer and determines the performance obligations and the contract price. The contract price is allocated to the distinct performance obligations in the contract and revenue is recognized when the performance obligations have been satisfied. A performance obligation is considered to be satisfied once the control of a product is transferred to the customer or the service is provided to the customer,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">meaning the customer has the ability to use and obtain the benefit of the goods or service, generally at product shipment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes receivables in an amount expected to be collected in a transaction. The Company’s payment terms are generally net </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">days of billing. Contracts do not contain significant financing components based on the typical period of time between delivery of products and collection of contract consideration. Certain types of customers may pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month. The Company invoices its customers upon shipment of product and records its sales upon shipment in accordance with its standard terms and conditions, unless underlying customer contracts specify otherwise. When necessary, the Company invoices and collects sales tax from its customers for sales of products. The Company has elected to exclude sales tax from the measurement of the transaction price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contract balances</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A receivable is recognized in the period the Company delivers goods or provides services or when the Company’s right to consideration is unconditional. The Company usually does not record contract assets because the Company has an unconditional right to payment upon satisfaction of the performance obligation, and therefore, a receivable is more commonly recorded than a contract asset. Receivables from contracts with customers are included within accounts receivable, net on the balance sheets.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contract liabilities include payments received in advance of performance under a contract and are satisfied as the associated revenue is recognized. When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with the amount allocated to those performance obligations is reflected as contract liabilities on the balance sheets and is deferred until control of these performance obligations is transferred to the customer. There are no contract liabilities as of December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contract costs</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under ASC 606, the Company is required to capitalize incremental costs to obtain customer contracts if the costs relate directly to a contract that can be specifically identified and expect to be recovered. These costs are required to be amortized to expense consistent with the transfer of the goods or services to the customer to which the asset relates. As a practical expedient, the Company recognizes any incremental costs to obtain a contract as an expense when incurred if the amortization period of the asset is one year or less. The Company did not have any capitalized contract costs as of and for the twelve months ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
CY2022 tlis Contract With Customer Net Revenue Collection Period
ContractWithCustomerNetRevenueCollectionPeriod
P30D
CY2022 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying statement of cash flows for the twelve-month period ended December 31, 2021 and the accompanying balance sheet as of the year ended December 31, 2021 reflects the Company's reclassification of grants receivables and unbilled grants receivables to accounts receivable, to conform to the presentation of the current period. The statement of cash flows for the twelve-month period ended December 31, 2021 reflects the Company's reclassification of the change in lease assets and liabilities into other long-term assets and liabilities, to confirm to the presentation in the current period.</span></p>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of credit risk and other risks and uncertainties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash, and accounts receivables. The Company’s cash is deposited in accounts at large financial institutions and its cash equivalents are primarily held in prime and U.S. government money market funds. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is subject to risks common to companies in the diagnostics industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, and protection of intellectual property rights.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Global economic conditions remain volatile resulting from the continuing and evolving effects of the COVID-19 pandemic, inflationary pressures, rising interest rates, the ongoing military conflict between Russia and Ukraine and related sanctions imposed against Russia and otherwise. The Company continues to evaluate the potential impact of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">these global issues on our current and future business operations, including our expenses, clinical trials and addressable markets as well as on our industry and healthcare system.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is dependent on key suppliers for certain manufacturing and research and development activities. An interruption in the supply of these materials could temporarily impact the Company’s ability to commercialize, manufacture inventory and perform research and development, testing and clinical trials related to its products. The Company is also dependent on its manufacturing partners that are critical to its ability to supply product to its end customers.</span></p>
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
4400000
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
3600000
CY2021 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022 tlis Inflation Reduction Act Of2022 Incometax Expense Benefit
InflationReductionActOf2022IncometaxExpenseBenefit
1000000000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15150000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9805000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12822000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3992000
CY2022Q4 tlis Property Plant And Equipment Before Construction Inprogress
PropertyPlantAndEquipmentBeforeConstructionInprogress
2328000
CY2021Q4 tlis Property Plant And Equipment Before Construction Inprogress
PropertyPlantAndEquipmentBeforeConstructionInprogress
5813000
CY2022Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
984000
CY2021Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
4715000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3312000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10528000
CY2022Q4 tlis Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
351000
CY2021Q4 tlis Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
5303000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
638000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1080000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
989000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6383000
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2022 tlis Sales To Customers
SalesToCustomers
0
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
4100000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1984000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
834000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
110000
CY2022 us-gaap Lease Cost
LeaseCost
4934000
CY2021 us-gaap Lease Cost
LeaseCost
2094000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
1360000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
1050000
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y9M18D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y2M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.070
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.052
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3832000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4381000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4503000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4628000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
4757000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
24988000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
47089000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
13507000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
33582000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3703000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29879000
CY2022Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote per share
CY2022Q3 tlis Trading Price
TradingPrice
1.00
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8590411
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.48
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6196000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4367446
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.08
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
65862
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.50
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3030143
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.86
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1459226
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
5.03
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8402626
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.52
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8402626
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.52
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y7M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2831700
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
4.97
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P8Y3M18D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.713
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.731
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.029
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.79
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.51
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5368000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9207000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1200000
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-113000000.0
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-192000000.0
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.060
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.077
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.009
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.008
CY2022 tlis Effective Income Tax Rate Reconciliation Permanent Deterrence Percentage
EffectiveIncomeTaxRateReconciliationPermanentDeterrencePercentage
-0.005
CY2021 tlis Effective Income Tax Rate Reconciliation Permanent Deterrence Percentage
EffectiveIncomeTaxRateReconciliationPermanentDeterrencePercentage
-0.002
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.274
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.293
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
66709000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
60966000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
8384000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
6655000
CY2022Q4 tlis Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
9420000
CY2021Q4 tlis Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
4221000
CY2022Q4 tlis Deferred Tax Assets Manufacturing Line And Production Equipment
DeferredTaxAssetsManufacturingLineAndProductionEquipment
27875000
CY2021Q4 tlis Deferred Tax Assets Manufacturing Line And Production Equipment
DeferredTaxAssetsManufacturingLineAndProductionEquipment
29153000
CY2022Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
12669000
CY2021Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
11076000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
2838000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
2877000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
17880000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
0
CY2022Q4 tlis Deferred Tax Assets Other Accruals
DeferredTaxAssetsOtherAccruals
905000
CY2021Q4 tlis Deferred Tax Assets Other Accruals
DeferredTaxAssetsOtherAccruals
141000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
147880000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
115089000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
140411000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
111024000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
7469000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
4065000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
0
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
167000
CY2022Q4 tlis Deferred Tax Liabilities Operating Lease Right Of Use Asset
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
7469000
CY2021Q4 tlis Deferred Tax Liabilities Operating Lease Right Of Use Asset
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
3898000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
7469000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
4065000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
29400000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
59700000
CY2022 tlis Percentage Of Net Operating Loss And Tax Credit Carryforwards Utilization Subject To Substantial Annual Limitation
PercentageOfNetOperatingLossAndTaxCreditCarryforwardsUtilizationSubjectToSubstantialAnnualLimitation
0.50
CY2022 tlis Net Operating Loss And Tax Credit Carryforwards Utilization Period
NetOperatingLossAndTaxCreditCarryforwardsUtilizationPeriod
P3Y
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
7244000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4841000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1729000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2403000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
8973000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
7244000
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022 tlis Pending Income Tax Examination
PendingIncomeTaxExamination
0
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-113012000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-192036000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26633241
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26633241
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22655339
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22655339
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.24
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.24
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.48
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.48
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38844469
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
39058363
CY2022 us-gaap Description Of Defined Contribution Pension And Other Postretirement Plans
DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
The Company has a qualified deferred compensation plan under Section 401(k) of the Internal Revenue Code of 1986, as amended (401(k) Plan).
CY2022 tlis Defined Contribution Plan Automatic Matching Contribution Basis
DefinedContributionPlanAutomaticMatchingContributionBasis
one-for-one
CY2022 tlis Defined Contribution Plan First Automatic Matching Contribution Plan Percent
DefinedContributionPlanFirstAutomaticMatchingContributionPlanPercent
0.03
CY2022 tlis Percentage Of Employees Eligible For Dollar Automatic Matching Contribution Plan
PercentageOfEmployeesEligibleForDollarAutomaticMatchingContributionPlan
0.50
CY2022 tlis Defined Contribution Plan On Dollar Automatic Matching Contribution Plan Percent
DefinedContributionPlanOnDollarAutomaticMatchingContributionPlanPercent
0.02
CY2022 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.04
CY2022 tlis Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
900000
CY2021 tlis Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
1100000
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0

Files In Submission

Name View Source Status
tlis-20221231_def.xml Edgar Link unprocessable
tlis-20221231_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0000950170-23-009197-index-headers.html Edgar Link pending
0000950170-23-009197-index.html Edgar Link pending
0000950170-23-009197.txt Edgar Link pending
0000950170-23-009197-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tlis-20221231.htm Edgar Link pending
tlis-20221231.xsd Edgar Link pending
tlis-ex10_18.htm Edgar Link pending
tlis-ex10_19.htm Edgar Link pending
tlis-ex10_20.htm Edgar Link pending
tlis-ex10_21.htm Edgar Link pending
tlis-ex10_22.htm Edgar Link pending
tlis-ex23_1.htm Edgar Link pending
tlis-ex31_1.htm Edgar Link pending
tlis-ex31_2.htm Edgar Link pending
tlis-ex32_1.htm Edgar Link pending
tlis-ex32_2.htm Edgar Link pending
tlis-20221231_lab.xml Edgar Link unprocessable
tlis-20221231_pre.xml Edgar Link unprocessable
tlis-20221231_htm.xml Edgar Link completed